There were 229 press releases posted in the last 24 hours and 153,317 in the last 365 days.

HIV Drugs Industry Insights, Forecast to 2024: The Market Will Decline at a CAGR of 2.5% during 2019-2024

/EIN News/ -- Dublin, April 16, 2019 (GLOBE NEWSWIRE) -- The "HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV virus, thereby reducing the risk of its transmission.

According to the report, the global HIV drugs market exceeded a value of US$ 24.7 Billion in 2018. Looking forward, the market value is projected to reach US$ 22.5 Billion by 2024, declining at a CAGR of 2.5% during 2019-2024.

This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc.

One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.

Market Summary

Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.

On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.

Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.

The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.

Key Questions Answered

  • How has the global HIV drugs market performed so far and how will it perform in the coming years?
  • What are the key regions in the global HIV drugs market?
  • Which are the popular class types in the global HIV drugs market?
  • What are the major distribution channels in the global HIV drugs market?
  • What are the various stages in the value chain of the global HIV drugs market?
  • What are the key driving factors and challenges in the global HIV drugs market?
  • What is the structure of the global HIV drugs market and who are the key players?
  • What is the degree of competition in the global HIV drugs market?
  • How are HIV drugs manufactured?

Topics Covered

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global HIV Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Price Analysis
5.4 Market Breakup by Drug Class
5.5 Market Breakup by Distribution Channel
5.6 Market Breakup by Region
5.7 Market Forecast
5.8 SWOT Analysis
5.9 Value Chain Analysis
5.10 Porters Five Forces Analysis

6 Market Breakup by Drug Class
6.1 Nucleoside Reverse Transcriptase Inhibitors
6.2 Multi-Class Combination Products
6.3 Protease Inhibitors
6.4 HIV Integrase Strand Transfer Inhibitors
6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
6.7 Fusion Inhibitors and Others

7 Market Breakup by Distribution Channel
7.1 Hospital Pharmacies
7.2 Retail Pharmacies
7.3 Online Pharmacies
7.4 Others

8 Market Breakup by Region
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Middle East and Africa
8.5 Latin America

9 HIV Drugs Manufacturing Process
9.1 Product Overview
9.2 Raw Material Requirements
9.3 Manufacturing Process
9.4 Key Success and Risk Factors

10 Competitive Landscape
10.1 Market Structure
10.2 Market Breakup by Key Players
10.3 Profiles of Key Players
10.3.1 Boehringer Ingelheim International GmbH
10.3.2 Merck & Co. Inc.
10.3.3 ViiV Healthcare
10.3.4 AbbVie
10.3.5 F. Hoffmann-La Roche Ltd.
10.3.6 Teva Pharmaceutical Industries Ltd.
10.3.7 Bristol-Myers Squibb
10.3.8 Gilead Sciences Inc.
10.3.9 Johnson & Johnson
10.3.10 Cipla Limited
10.3.11 Daiichi Sankyo
10.3.12 Emcure
10.3.13 Hetero Drugs
10.3.14 Mylan

For more information about this report visit https://www.researchandmarkets.com/r/frdas

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Infectious Diseases Drugs, HIV/AIDS Drugs 

22157.jpg


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.